Mosunetuzumab-a newly emerged hope in relapse or refractory B-cell lymphomas

doi:10.15406/ppij.2023.11.00423

eISSN: 2379-6367

Pharmacy & Pharmacology International Journal

Editorial Volume 11 Issue 6

Mosunetuzumab-a newly emerged hope in relapse or refractory B-cell lymphomas

Nida Sajid Ali Bangash

Verify Captcha

Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.

School of Pharmacy, Monash University Malaysia, Malaysia

Correspondence: Nida Sajid Ali Bangash, School of Pharmacy, Monash University, Malaysia

Received: December 28, 2023 | Published: December 29, 2023

Citation: Bangash NSA. Mosunetuzumab-a newly emerged hope in relapse or refractory B-cell lymphomas. Pharm Pharmacol Int J. 2023;11(6):208. DOI: 10.15406/ppij.2023.11.00423

Download PDF

Introduction

Non-Hodgkin lymphoma (NHL), is type of cancer that begins in the lymphatic system which is part of our body’s immune defense system. Among this type the most prevalent is follicular lymphoma (FL) and is characterized by the aggregation or lump formation of abnormal lymphocytes either in the lymph nodes or other organs. This helps in identifying the tumor burden and the stage of FL. The risk to encounter cases with relapse or refractory disease is higher which may affect patient’s survival and hence quality of life (QoL). In the light of these patient challenges, it is important to introduce therapies that can directly target the specific sites and improve disease prognosis.

Mosunetuzumab

Mosunetuzumab is an anti-neoplastic agent and a bispecific CD20- directed CD3 T-cell engager.

Safety and efficacy

Since decades conventional therapies such as chemotherapy and radiation therapy been improving patient’s survival in cancer. Monoclonal antibodies such as rituximab in the past had shown promising results as a frontline therapy but many patients with FL will still present with relapse or refractory disease and complications of therapy. Therefore, there is an unmet need to develop target specific and well tolerated therapy. In phase II trials, fixed-duration of 21-days and 28-days cycle of mosunetuzumab has shown improvements in the response rate among patients with R/R FL after two prior systemic therapies. Additionally, mosunetuzumab has a manageable toxicity profile as majority reported adverse events were of low-grade severity.